Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
- PMID: 18539529
- DOI: 10.1016/S1470-2045(08)70153-0
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
Abstract
Background: Emerging evidence on body composition suggests that sarcopenic obesity (obesity with depleted muscle mass) might be predictive of morbidity and mortality in non-malignant disease and also of toxicity to chemotherapy. We aimed to assess the prevalence and clinical implications of sarcopenic obesity in patients with cancer.
Methods: Between Jan 13, 2004, and Jan 19, 2007, 2115 patients with solid tumours of the respiratory or gastrointestinal tract from a cancer treatment centre serving northern Alberta, Canada, were identified. Available lumbar CT images of the obese patients were analysed for total skeletal muscle cross-sectional area; these values were also used to estimate total body fat-free mass (FFM).
Findings: Of the 2115 patients initially identified, 325 (15%) were classified as obese (body-mass index [BMI] > or =30). Of these obese patients, 250 had CT images that met the criteria for analysis. The remaining 75 patients were recorded as without assessable scans. Obese patients had a wide range of muscle mass. Sex-specific cut-offs that defined a significant association between low muscle mass with mortality were ascertained by optimum stratification analysis: 38 (15%) of 250 patients who had assessable CT images that met the criteria for analysis were below these cut-offs and were classified as having sarcopenia. Sarcopenic obesity was associated with poorer functional status compared with obese patients who did not have sarcopenia (p=0.009), and was an independent predictor of survival (hazard ratio [HR] 4.2 [95% CI 2.4-7.2], p<0.0001). Estimated FFM showed a poor association with body-surface area (r(2)=0.37). Assuming that FFM represents the volume of distribution of many cytotoxic chemotherapy drugs, we estimated that individual variation in FFM could account for up to three-times variation in effective volume of distribution for chemotherapy administered per unit body-surface area, in this population.
Interpretation: This study provides evidence of the great variability of body composition in patients with cancer and links body composition, especially sarcopenic obesity, to clinical implications such as functional status, survival, and potentially, chemotherapy toxicity.
Comment in
-
Excess baggage: sarcopenia, obesity, and cancer outcomes.Lancet Oncol. 2008 Jul;9(7):605-7. doi: 10.1016/S1470-2045(08)70160-8. Lancet Oncol. 2008. PMID: 18598925 No abstract available.
Similar articles
-
Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25. J Clin Oncol. 2013. PMID: 23530101
-
Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.Clin Nutr. 2016 Jun;35(3):724-30. doi: 10.1016/j.clnu.2015.05.011. Epub 2015 May 27. Clin Nutr. 2016. PMID: 26065721 Clinical Trial.
-
Fat and fat-free mass as important determinants of body composition assessment in relation to sarcopenic obesity.Rocz Panstw Zakl Hig. 2023;74(1):59-69. doi: 10.32394/rpzh.2023.0243. Rocz Panstw Zakl Hig. 2023. PMID: 37010407
-
Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy.Ann Oncol. 2018 Feb 1;29(suppl_2):ii1-ii9. doi: 10.1093/annonc/mdx810. Ann Oncol. 2018. PMID: 29506228 Review.
-
Sarcopenic obesity: What about in the cancer setting?Nutrition. 2022 Jun;98:111624. doi: 10.1016/j.nut.2022.111624. Epub 2022 Feb 4. Nutrition. 2022. PMID: 35436691 Review.
Cited by
-
Impact of pre-sarcopenia on outcomes of transarterial chemoembolization in unresectable hepatocellular carcinoma.Sci Rep. 2024 Aug 20;14(1):19249. doi: 10.1038/s41598-024-70266-0. Sci Rep. 2024. PMID: 39164379 Free PMC article.
-
Unveiling hidden outcomes in malignant gastric outlet obstruction research - insights from a "Pancreas 2000" review.World J Gastrointest Endosc. 2024 Aug 16;16(8):451-461. doi: 10.4253/wjge.v16.i8.451. World J Gastrointest Endosc. 2024. PMID: 39155997 Free PMC article. Review.
-
Prognostic significance of preoperative creatine kinase in resected thymic epithelial tumors.J Thorac Dis. 2024 Jul 30;16(7):4186-4194. doi: 10.21037/jtd-23-1797. Epub 2024 Jul 18. J Thorac Dis. 2024. PMID: 39144315 Free PMC article.
-
Computed tomography (CT)-based skeletal muscle vertebral-related index to assess low muscle mass in patients with non-small cell lung cancer.Quant Imaging Med Surg. 2024 Aug 1;14(8):5737-5747. doi: 10.21037/qims-24-120. Epub 2024 Jul 11. Quant Imaging Med Surg. 2024. PMID: 39144051 Free PMC article.
-
[Sarcopenia and immune-related toxicity in patients with malignant melanoma undergoing immune checkpoint inhibition].Dermatologie (Heidelb). 2024 Aug 14. doi: 10.1007/s00105-024-05405-9. Online ahead of print. Dermatologie (Heidelb). 2024. PMID: 39143426 German.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous